Navigation Links
International TGen-led team finds link between brain protein and Alzheimer's disease

PHOENIX, Ariz. Sept. 15, 2008 Investigators at the Translational Genomics Research Institute (TGen) today announced a link between the brain protein KIBRA and Alzheimer's disease, a discovery that could lead to promising new treatments for this memory-robbing disorder.

The new discovery builds on a previous TGen-led study published in the prestigious journal Science, which showed a genetic link between KIBRA and memory in healthy adults.

In the new study, TGen researchers found that carriers of a memory-enhancing flavor of the KIBRA gene had a 25 percent lower risk of developing Alzheimer's disease.

The findings were reported Saturday in the online edition of Neurobiology of Aging, a Philadelphia-based peer-review journal that generally focuses on how aging affects the nervous system.

"This research suggests that KIBRA, and possibly some of the proteins with which it interacts, may play a role in Alzheimer's disease,'' said Dr. Matthew Huentelman, an investigator in TGen's Neurogenomics Division and the paper's senior author.

The critical difference found in KIBRA, a protein so named because it is commonly found in the kidneys and brain, was that those individuals with the T-allele gene were less likely to develop Alzheimer's than those with the C-allele. Alleles are those genetic markers A, C, G or T that determine such inherited traits as eye and hair color, or susceptibility to disease.

"We are now beginning to dig deeper regarding the genetic sequence of KIBRA in individuals carrying, and not carrying, the T-allele. We believe this variation causes a potential lifelong difference in the total levels of KIBRA in the brain, and that this may influence one's risk for Alzheimer's," said Huentelman, who led a team that worked with several Arizona institutions, as well as other national and international universities and research institutions.

Dr. Eric Reiman, clinical director of TGen's Neurogenomics Division and executive director of the Banner Alzheimer's Institute, said, "This study suggests a link between the inherited genes involved in normal human memory and the predisposition to Alzheimer's disease.

"It provides promising new targets at which to aim new treatments to stave off Alzheimer's and improve memory," said Reiman, who also is director of the Arizona Alzheimer's Consortium and a contributor to the study.

The findings announced today are built on a 2006 study led by collaborative teams from Arizona and Zurich, Switzerland, and published in the journal Science. That pioneering TGen research revealed a link between KIBRA and memory, in which healthy adults with the KIBRA T-allele performed better on memory tests than those without this gene.

In the most recent analysis, Huentelman's team confirmed a link between KIBRA and Alzheimer's in three different ways:

  • Using TGen's powerful analytic tools to find a genetic association between the KIBRA gene and Alzheimer's disease, comparing more than 1,700 living and deceased people, with and without the disorder.

  • Using gene expression tools to find that KIBRA, and genes for other molecules that interact with KIBRA, were significantly altered in the neurons of people who had Alzheimer's disease, but not in individuals without the disorder.

  • Using a brain imaging technique called positron emission tomography (PET) to find that cognitively-normal, late-middle-aged people lacking the protective T-allele gene had reduced activity in parts of the brain usually affected by Alzheimer's.

Genetic association study

In a study of 702 deceased persons diagnosed with Alzheimer's, and 1,026 living and deceased persons with and without Alzheimer's, researchers found that non-carriers of the KIBRA T-allele had increased risk of late-onset Alzheimers.

The genotyped samples came from five centers, including three European organizations representing German, Dutch and Norwegian populations.

Gene expression study

The gene expression study examined tissues from six regions of the brain among 47 deceased individuals. The brain tissue samples were provided by three Alzheimer's disease centers: Washington University in St. Louis, Mo.; Duke University in Durham, N.C.; and Sun Health Research Institute in Sun City, Ariz.

KIBRA, and a subset of other molecules directly interacting with it, were significantly altered in regions of the brain involved in Alzheimer's disease pathology. The regions investigated included the hippocampus, entorhinal cortex, posterior cingulate cortex, middle temporal gyrus, and superior frontal gyrus. However, they were not altered in a region of the brain typically unaffected by the disease -- the primary visual cortex.

Positron Emission Tomography scans

PET scans of 67 non-carriers of the KIBRA T-allele, and 69 carriers -- all with close relatives diagnosed with Alzheimer's -- showed that non-carriers exhibited, on average, similar alterations in the metabolic activity of key brain regions known to be altered in the earliest stages of the disease. All 136 individuals were mentally-normal, late-middle-aged Phoenix-area volunteers solicited from newspaper advertisements. They ranged in age from 47 to 68, with an average age of 55.

Scans showed that individuals without the KIBRA T-allele -- those with only KIBRA C-alleles from their mother and from their father -- had less metabolic brain activity when compared to those individuals carrying the T-allele -- from either their mother or father, or both. These differences were found in the precuneus and posterior cingulated regions of the brain affected in the earliest stages of Alzheimer's.

Previous work led by Reiman illustrated a similar finding when individuals were grouped according to whether they carried the most powerful genetic indicator for Alzheimer's -- the epsilon 4 allele of apolipoprotein E. In the current study, the effects of this allele were controlled for, yet similar observations were made. This suggests that KIBRA may play a role in a convergent biological risk pathway for the disease.


Contact: Steve Yozwiak
The Translational Genomics Research Institute

Related biology news :

1. International experts collect alpine fungi in Beartooth Mountains of Montana
2. Corporate Safe Specialists Launches International Sales Efforts
3. International team reveals first prognosticator of survival in aggressive cancer
4. [video] Michael DePasquale, CEO of BIO-key International, Inc., Discusses Q2 2008 Revenue Growth on WallSt.nets 3-Minute Press Show
5. NYU Langone Medical Centers tip sheet to the International Conference on Alzheimers Disease 2008
6. International conference to release new findings on smell and taste
7. International team identifies 21 new genetic risk factors for Crohns disease
8. 2008 ASABE Annual International Meeting
9. The 12th International Behavioral Ecology Congress held at Cornell University, Aug. 10-14
10. Biotechnology key to developing sustainable industries says international panel
11. BBVA Foundation international study on attitudes to stem cell research
Post Your Comments:
(Date:11/11/2015)... , Nov. 11, 2015   MedNet Solutions , ... spectrum of clinical research, is pleased to announce that it ... Clinical Trials (PCT) event, to be held November 17-19 ... able to view live demonstrations of iMedNet ... learn how iMedNet has been able to deliver ...
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
(Date:10/29/2015)... 2015  Rubicon Genomics, Inc., today announced an ... its DNA library preparation products, including the ThruPLEX ... Plasma-seq kit. ThruPLEX Plasma-seq has been optimized for ... libraries for liquid biopsies--the analysis of cell-free circulating ... in cancer and other conditions. Eurofins Scientific is ...
Breaking Biology News(10 mins):
(Date:11/26/2015)... , England , November 26, 2015 /PRNewswire/ ... Medical, an innovative medical device company specializing in imaging technologies, ... from the European Commission as part of the Horizon 2020 ... company to carry out a large-scale clinical trial in breast ...      (Logo: , --> ...
(Date:11/25/2015)... , November 25, 2015 2 ... première fois les différences entre les souches bactériennes ... celles des êtres humains . Ces recherches ... et envisager la prise en charge efficace de ... diagnostiqués chez les chats .    --> ...
(Date:11/25/2015)... DIEGO , Nov. 25, 2015  Neurocrine Biosciences, ... Kevin Gorman , President and CEO of Neurocrine Biosciences, ... Healthcare Conference in New York . ... to visit the website approximately 5 minutes prior to ... A replay of the presentation will be available on ...
(Date:11/25/2015)... DIEGO , Nov. 25, 2015 Orexigen® ... management will participate in a fireside chat discussion at ... New York . The discussion is scheduled ... .  A replay will be ... Media Contact:McDavid Stilwell  , Julie NormartVP, Corporate Communications ...
Breaking Biology Technology: